Phase 2 N=31 Vitamin D in Ventilated ICU Patients
Respiratory Failure
Primary: Number of Participants With Plasma 25(OH)D Concentration >30ng/mL at Baseline — 2; 2; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=224 A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
Osteoporosis
Primary: Change in Lumbar Spine Areal Bone Mineral Density (BMD) — 0.094; 0.055 gram per square centimeter (g/cm^2) — p=<.0001
Phase 4 N=34 Pharmacogenomics of Antiplatelet Response
Atherosclerosis
Primary: Differential Gene Expression — 77.1 FPKM for HBG1 Gene — p=<0.000005
Phase 1 N=84 A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
Healthy
Primary: Percentage of Participants With an Immune Response to Tetanus and Pneumococcal Vaccinations — 52.6; 51.2; 89.5; 90.2 percentage of participants
Phase 3 N=12,896 Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System
Human Papillomavirus Infection
Primary: Adjunct Study Arm: Compare Assay Performance for Aptima HPV Assay to a FDA-Approved HPV Assay for Detecting CIN2+ — 15; 5; 299; 500 participants
Phase 2 N=79 Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL)
Primary: Response Per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Criteria — 66.7; 83.3; 68.8; 39.4 percentage of patients
Phase 4 N=1,269 Starting Treatment With Agonist Replacement Therapies (START)
Opiate-related Disorders
Primary: Hepatic Safety — 278; 318; 41; 62 participants — p=< 0.05
Phase 2 N=9 Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
Liver Cancer · Pancreatic Cancer
Primary: Median Overall Survival (OS) — 14.09 months
Phase 4 N=139 Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Number of Participants Who Correctly Used the Device at the Start of Handling the Device — 55; 49 Participants — p=0.451
Phase 3 N=193 An RCT to Evaluate the Effect of a New Skin Care Regimen on SBF in Those With Podoconiosis
Non-filarial Elephantiasis
Primary: Change in TEWL at Top of Outer Lower Legs — 12.74; 13.43; 13.52; 13.27 g/m2/h — p=<0.001
Phase 3 N=304 To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways
Pulmonary Disease, Chronic Obstructive
Primary: Endurance Time During Endurance Shuttle Walk Test (ESWT) to Symptom Limitation After 8 Weeks — 244.07; 254.18; 315.32; 355.73 Second — p=0.0002
Phase 4 N=716 A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
Migraine Disorders
Primary: Change From Baseline in the Frequency of Headache Days — 22.0; -10.7 headache days
N/A N=66 Cardiac Resynchronization Therapy Efficacy Enhancements
Atrial Fibrillation
Primary: Percentage of Effective CRT Pacing During AF (Non-inferiority Test) — 80.8; 87.8 percentage of effective CRT pacing — p=<0.0001
Phase 3 N=60 Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years
Herpes Zoster
Primary: Number of Subjects With Anti-Glycoprotein E (Anti-gE) Antibody Concentrations Higher Than or Equal to (≥)18 Milli-international Units Per Milliliter (mIU/mL) — 29; 29…
N/A N=331 PROs in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With Pregabalin
Low-Back Pain
Primary: Change From Baseline in Pain Related Sleep Interference Scale (PRSIS - Past Week Recall) — 3.1; 2.9; -1.306; -0.357 scores on a scale — p=<0.001